CV Sciences (CVSI) Net Cash Flow Growth (1y) (2012 - 2026)
CV Sciences (CVSI) Net Cash Flow Growth (1y) (2012 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | NCF Growth (1y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 43.89 Bn | 42.93 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 42.98 Bn | 39.33 Bn | 2.15 Bn | -117.27% |
| 3 | Zoetis | 31.54 Bn | 29.86 Bn | 1.05 Bn | -167.84% |
| 4 | Takeda Pharmaceutical | 28.61 Bn | 22.81 Bn | 5.10 Bn | -290.21% |
| 5 | United Therapeutics | 22.15 Bn | 19.48 Bn | 683.80 Mn | 270.63% |
| 6 | Viatris | 18.75 Bn | 17.86 Bn | 1.46 Bn | -367.42% |
| 7 | Neurocrine Biosciences | 15.56 Bn | 15.17 Bn | 935.80 Mn | -7.60% |
| 8 | Elanco Animal Health | 11.74 Bn | 11.21 Bn | 798.00 Mn | 272.00% |
| 9 | Dr Reddys Laboratories | 10.11 Bn | 9.95 Bn | - | - |
| 10 | CV Sciences | 4.10 Mn | 3.84 Mn | 1.45 Mn | -157.75% |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -157.75% |
| Mar 31, 2026 | -91.64% |
| Dec 31, 2025 | 90.21% |
| Sep 30, 2025 | -209.76% |
| Jun 30, 2025 | 138.59% |
| Mar 31, 2025 | 154.89% |
| Dec 31, 2024 | -59.82% |
| Sep 30, 2024 | 1,168.09% |
| Jun 30, 2024 | -118.85% |
| Mar 31, 2024 | -734.95% |
| Dec 31, 2023 | 38.26% |
| Sep 30, 2023 | -288.00% |
| Jun 30, 2023 | 173.66% |
| Mar 31, 2023 | -90.32% |
| Dec 31, 2022 | -85.26% |
| Sep 30, 2022 | 101.92% |
| Jun 30, 2022 | 51.02% |
| Mar 31, 2022 | -6.75% |
| Dec 31, 2021 | 81.48% |
| Sep 30, 2021 | 35.37% |